Your current location is:{Current column} >>Text

Envista cut to Sell at Goldman Sachs, CRISPR to Underperform: 4 big analyst cuts By

{Current column}68People have watched

Introduction— Here is your Pro Recap of the biggest analyst cuts you may have missed today: downgrades at ...

— Here is Forex Group Official Websiteyour Pro Recap of the biggest analyst cuts you may have missed today: downgrades at Envista, CRISPR Therapeutics, Super Micro Computer, and Trust.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Envista cut to Sell at Goldman Sachs, CRISPR to Underperform: 4 big analyst cuts By

Envista slashed to Sell at Goldman Sachs

Envista (NYSE:) shares dropped more than 2% pre-market today after Goldman Sachs downgraded the company to Sell from Neutral with a price target of $22.00.

According to the analysts, the downgrade is driven by concerns about Envista's product positioning in implants and equipment, a perceived lack of innovation in its pipeline, and competitive pressures. They believe these factors may hinder Envista's ability to quickly re-accelerate growth towards its mid-single digit to high-single digit target and achieve margin expansion.

The analysts noted that the dental industry is entering 2024 amidst uncertain market conditions, marked by a decline in patient traffic, elective demand, and capital expenditures in dental practices in the second half of 2023. “Beyond current macro conditions, we see headwinds to longer run growth from limited product innovation, ASP pressure in equipment, and challenging competitive dynamics in implants and clear aligners,” commented Goldman Sachs.

CRISPR Therapeutics cut at TD Cowen

TD Cowen downgraded Crispr Therapeutics (NASDAQ:) to Underperform from Market Perform with a price target of $30.00, as reported in real-time on InvestingPro.

While acknowledging last week’s FDA approval of Casgevy as a significant scientific achievement for gene editing, the analysts expressed skepticism about its broad application. They suggest that the current high valuation of CRISPR Therapeutics is largely due to a recent aggressive short squeeze rather than fundamental market factors.

InvestingPro | Outsmart the Market

Two more downgrades

Susquehanna downgraded Super Micro Computer (NASDAQ:) to Negative from Neutral with a price target of $160.00. Shares fell more than 2% pre-market today.

The downgrade is primarily due to increased gross margin pressure arising from heightened competition and rising costs for Memory/Storage. Additionally, the diversification in server architecture, especially for AI applications, necessitates higher inventories to accommodate a wider range of stock-keeping units (SKUs) for each configuration.

Our estimate change and downgrade is based on industry fundamentals. We applaud SuperMicro's strategy of enabling mass customization of next gen server architecture, including AI Servers. However, consistent with our industry view and recent checks from throughout the supply chain, there are several factors that have led to estimate reduction.

Vornado Realty Trust (NYSE:) shares fell more than 1% pre-market today after Evercore ISI downgraded the company to Underperform from In Line with a price target of $28.00 (from $23.00).

Amid whipsaw markets and a slew of critical headlines, seize on the right timing to protect your profits: Always be the first to know with InvestingPro.

InvestingPro | Be The First To Know

Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!

Tags:

Related articles